Alto Neuroscience (ANRO) Income from Continuing Operations (2023 - 2026)
Alto Neuroscience (ANRO) reported Income from Continuing Operations of 26122000.0 for Q1 2026, down 64.82% on a YoY basis from 74248130.92 in Q1 2025, and down 64.09% sequentially from 15919000.0 in Q4 2025.
Alto Neuroscience (ANRO) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Alto Neuroscience (ANRO) has 4 years of Income from Continuing Operations data on file, last reported at 26122000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 64.82% year-over-year to 26122000.0; the trailing twelve-month figure through Mar 2026 stood at 2274459000.0 (down 3461.52% YoY), and the FY2025 full-year result was 111903000.0, down 15.18% from the prior year.
- Income from Continuing Operations slipped to 26122000.0 in Q1 2026, from 15919000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 7295000.0 in Q1 2023 to a low of 1853419000.0 in Q3 2025.
- A 4-year average of 183690538.46 and a median of 15849000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 4.76% in 2025, while the deepest fall reached 10975.11% in 2025.
- Tracing ANRO's Income from Continuing Operations over 4 years: stood at 10925000.0 in 2023, then sank by 39.08% to 15195000.0 in 2024, then dropped by 4.76% to 15919000.0 in 2025, then sank by 64.09% to 26122000.0 in 2026.
- Business Quant data shows ANRO's Income from Continuing Operations at 26122000.0 in Q1 2026, 15919000.0 in Q4 2025, and 1853419000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Alto Neuroscience | 881.86 Mn | 881.86 Mn | - | -26.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.12 Mn |
| Dec 31, 2025 | -15.92 Mn |
| Sep 30, 2025 | -1.85 Bn |
| Jun 30, 2025 | -379.00 Mn |
| Mar 31, 2025 | -15.85 Mn |
| Dec 31, 2024 | -15.20 Mn |
| Sep 30, 2024 | -16.74 Mn |
| Jun 30, 2024 | -16.08 Mn |
| Mar 31, 2024 | -13.17 Mn |
| Dec 31, 2023 | -10.93 Mn |
| Sep 30, 2023 | -9.40 Mn |
| Jun 30, 2023 | -8.86 Mn |
| Mar 31, 2023 | -7.30 Mn |